康德莱医械(01501.HK)子公司引资815万人币
康德莱医械(01501.HK)公布,董事会主席兼总经理梁栋科以及上海康德莱研究所的总经理陈晓,担任普通合夥人的股份激励平台,将分别向公司子公司上海翰淩投资581.5万及233.5万元人民币,认购其10%及约4.02%扩大後的股权。
上海翰淩的股本将由5,000万增至5,815万元人民币,增资及股权认购事项完成後,公司於上海翰淩的股权将由69%降至约59.33%,而上海翰淩仍将为公司的非全资子公司。
公司预期,增资及股权认购事项将提供额外的资金,以支持正在进行及潜在的研发项目,包括研发成本、材料、设备、人力资源、临床试验、检验、注册及取样等成本及开支。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.